Deadline in Lawsuit for Investors in Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Shares Announced by Shareholders Foundation...
September 21 2015 - 8:46PM
The Shareholders Foundation, Inc. announces that a lawsuit was
filed in Maryland on behalf of certain purchasers of shares of
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) over alleged
Securities Laws Violations by Northwest Biotherapeutics, Inc.
Investors who purchased shares of Northwest Biotherapeutics, Inc
(NASDAQ:NWBO) have certain options and for certain investors are
short and strict deadlines running. Deadline: October 26, 2015.
(NASDAQ:NWBO) investors should contact the Shareholders Foundation
at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff claims that defendants made certain allegedly
false and/or misleading statements and/or allegedly failed to
disclose that Northwest Biotherapeutics’ claims regarding positive
results from its DCVax-Direct Trial were based on preliminary and
unconfirmed trial results, that the DCVax-Direct Trial results on
which Northwest Biotherapeutics reported had not been reviewed or
analyzed by the hospitals conducting the trials, that Northwest
Biotherapeutics’ statements about DCVax-Direct were derived from
patient case report forms, which the hospitals were obliged to send
to the Company only because it sponsored the study, that Northwest
Biotherapeutics was the subject of an aggressive stock promotion
campaign which included promoters using fictitious identities and
false credentials, that German regulators required additional
information from Northwest Biotherapeutics in order for its DCVax-L
Trial to continue uninterrupted, and that as a result of the above,
Northwest Biotherapeutics’ financial statements were materially
false and misleading at all relevant times.
On June 19, 2014, an article was published that stated that "The
prestigious MD Anderson Cancer Center issued a stern rebuke to
Northwest Biotherapeutics (NWBO) for making promotional,
unjustified claims about results from an ongoing clinical
trial of an experimental cancer vaccine known as
DCVax-Direct.”
On July 7, 2014, a report stated that Northwest Biotherapeutics
has been the subject of a massive promotional campaign which has
seen the stock price soar. And, in some cases, authors have used
fictitious identities and fake credentials within healthcare or
finance. In fact they are simply paid writers.
On August 21, 2015, news broke that Northwest Biotherapeutics’
Phase 3 DCVax-L brain cancer treatment clinical trial in Germany
was temporarily halted.
Those who purchased (NASDAQ:NWBO) shares have certain options
and should contact the Shareholders Foundation, Inc. by e-mail at
mail@shareholdersfoundation.com or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio
legal monitoring and a settlement claim filing service, which does
research related to shareholder issues and informs investors of
securities class actions, settlements, judgments, and other legal
related news to the stock/financial market. The Shareholders
Foundation, Inc. is not a law firm. The information is provided as
a public service. It is not intended as legal advice and should not
be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024